PRGOのチャート
PRGOの企業情報
| symbol | PRGO |
|---|---|
| 会社名 | Perrigo Company plc （PRGO ペリゴ） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 ぺリゴ(Perrigo Company PLC)(旧名: Perrigo Company Limited)は店頭（OTC）消費財および専門製薬会社である。同社は消費者ヘルスケア（CHC）事業、ブランド消費者医療（BCH）事業、処方薬（Rx）事業および専門科学事業を運営する。同社はOTCヘルスケア製品を製造し、店舗ブランド市場向けの乳児用調合乳を供給する。また、一般的な拡張局所処方製品を提供する。CHC事業は、OTC店舗ブランド製品の販売に従事する。BCH事業は、多数の欧州のOTCブランドを開発・製造・販売・流通する。専門科学事業は、多発性硬化症の治療に重点を置いた資産、特に医薬品Tysabriを含む。 ペリゴはアイルランドの大手製薬会社。咳や風邪、アレルギ―用などの市販薬、ジェネリック、処方箋薬を扱う。市場は米国、英国、メキシコ、イスラエル、オ―ストラリア、カナダ、中国と南米。また、多発性硬化症の治療に焦点を当てた薬を開発、製造する。その他に、乳幼児向け飲料や離乳食、栄養サプリメントも扱う。本社はダブリン。 perrigo company plc, a top five global over-the-counter (otc) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. from its beginnings in 1887 as a packager of generic home remedies, perrigo, headquartered in ireland, has grown to become the world's largest manufacturer of otc products and supplier of infant formulas for the store brand market. the company is also a leading provider of branded otc products, generic extended topical prescription products and receives royalties from multiple sclerosis drug tysabri®. perrigo provides “quality affordable healthcare products®” across a wide variety of product categories and geographies primarily in north america, europe, and australia, as well as other key markets including israel and china. visit perrigo online at (http://www.perrigo.com). |
| 本社所在地 | The Sharp Building Hogan Place Dublin 2 IRL |
| 代表者氏名 | Marry Laurie Brlas |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +353 1-709-4000 |
| 設立年月日 | 41426 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 10600人 |
| url | www.perrigo.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 905.50000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 6543.64700 |
| 売上高 | 売上高（百万ドル） 4731.70000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 9232.94700 |
| 当期純利益 | 当期純利益（百万ドル） 130.90000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Perrigo Company PLC revenues decreased 4% to $4.73B. Net income before extraordinary items decreased 3% to $131M. Revenues reflect RX Pharmaceuticals segment decrease of 15% to $824.2M Other segment decrease from $55.6M to $0K CHCA segment decrease of 1% to $2.41B. Net income also reflects CHCA segment income decrease of 67% to $147.6M RX Pharmaceuticals segment income decrease of 28% to $222.6M. |
PRGOのテクニカル分析
PRGOのニュース
Perrigo Picks Former Bayer Executive As New CEO 2023/06/08 13:37:57 Benzinga
Perrigo Co PLC (NYSE: PRGO ) disclosed the appointment of Patrick Lockwood-Taylor as its new President, CEO and member of the Board of Directors, effective June 30, 2023 . Before joining Perrigo, Lockwood-Taylor served dual roles at Bayer A.G .(OTC: BAYRY ) as President of the U.S. business and Regional President … Full story available on Benzinga.com
Perrigo Appoints Patrick Lockwood-Taylor as President and CEO 2023/06/08 11:40:00 PR Newswire
DUBLIN, June 8, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced the appointment of industry professional Patrick Lockwood-Taylor as its new President, Chief Executive Officer and member of the Board of Directors,…
Perrigo Company: Still Not Getting There 2023/05/18 19:12:00 Seeking Alpha
Poor execution and higher debt assumed caused uncertainty on Perrigo Company shares. Click here for a review of PRGO stock prospects.
Perrigo wins FDA nod for Nicotine Coated Mint Lozenge 2023/05/16 17:19:01 Seeking Alpha
Perrigo Company (PRGO) announced Tuesday that the FDA issued final approval for its anti-smoking product Nicotine Coated Mint Lozenges for OTC use. Read more here.
Recalled Gerber baby formula was sent to US retailers after recall began, wholesaler says 2023/05/16 16:00:04 WNYT
NEW YORK (AP) — An infant formula recalled over potential bacteria contamination was distributed to retailers across eight states even after the recall begun, according to a release published by the U.S. Food and Drug Administration this week. In March, Perrigo Co. issued a voluntary recall of certain lots of its Gerber Good Start SootheProTM Powdered Infant Formula “out of an abundance of caution” due to the possible presence of Cronobacter sakazakii, a germ that can cause serious or deadly infections in infants. The recall impacted Gerber Good Start formula manufactured between Jan. 2 and Jan. 18 at the Perrigo’s Gateway Eau Claire, Wisconsin, facility. The recalled formula was sold in three different sizes at retailers nationwide, according to a March 17 recall notice. Cooperative food wholesaler Associated Wholesale Grocers, however, distributed the 12.4-ounce verison of the recalled product to its Nashville Division retailers after Perrigo’s initial recall notice was published. As a result, the recalled product was distributed to supermarkets across Alabama, Georgia, Indiana, Kentucky, Ohio, Tenneessee, Virginia and West Virgina, Associated Wholesale Grocers said Saturday.
Ridgewood Investments LLC Buys 3, Sells 2 in 4th Quarter 2023/01/20 00:00:11 GuruFocus
Related Stocks: GSK , CAH , GILD , D , PRGO ,
Top 5 4th Quarter Trades of Seelaus Asset Management LLC 2023/01/19 20:00:14 GuruFocus
Related Stocks: VRRM , ORCL , J , GNRC , PRGO ,
Perrigo Stock: Still Languishing But Short-Term Trend Offers Encouragement (NYSE:PRGO) 2023/01/18 14:33:53 Seeking Alpha
Shares of the health company have had an excellent 4 weeks. However, a thick wall of overhead resistance from a sustained pattern of lower highs is on the technical chart. Read more here.
$2 Billion Worldwide Nicotine Gum Industry to 2027 - Featuring Novartis, Perrigo, Pfizer and Takeda Pharmaceutical Among Others - ResearchAndMarkets.com 2023/01/17 13:50:00 Business Wire
The
Perrigo Company Plc (PRGO) Trading Report 2022/12/14 16:45:00 Stock Traders Daily
Trading Report for Perrigo Company Plc PRGO With Buy and Sell Signals
US ranitidine litigation unlikely to have impact on Indian pharma: Analysts 2022/08/18 19:50:00 Business Standard
Sun Pharmaceuticals, Dr Reddy''s Laboratories, Perrigo and Teva have agreed to a combined settlement of $5 mn with cancer patient Joseph Bayer
Perrigo responds to ''misleading and inaccurate information'' on Zantac claims 2022/08/17 21:12:23 Seeking Alpha
Perrigo Wednesday afternoon said that an August 16 notice of dismissal of claims and impending trial against the branded companies that manufactured Zantac did not involve the company.
Perrigo Company plc Still Hasn’t Convinced Analysts? 2022/08/17 20:00:00 Stocks Register
Perrigo Company plc (NYSE:PRGO) price is hovering lower on Tuesday, August 16, dropping -9.00% below its previous close. A look at today’s price movement shows that the recent level at last check reads $41.84, with intraday deals fluctuating between $41.38 and $42.21. The company’s 5Y monthly beta was ticking 0.93. Taking into account the 52-week … Perrigo Company plc Still Hasn’t Convinced Analysts? Read More »
Teva, Perrigo drop after settlements for dismissal of Zantac trial 2022/08/17 16:07:08 Seeking Alpha
Generic drugmakers Teva Pharmaceutical Industries (TEVA) and Perrigo Company (PRGO) traded sharply lower on Wednesday after Bloomberg reported that the companies settled a lawsuit over…
Perrigo Co PLC (PRGO) Q2 2022 Earnings Call Transcript 2022/08/10 12:37:29 AlphaStreet
Perrigo Co PLC (NYSE: PRGO) Q2 2022 earnings call dated Aug. 09, 2022 Corporate Participants: Bradley Joseph — Vice President, Global Investor Relations and Corporate Communications Eduardo Bezerra — Executive Vice President and Chief […] The post Perrigo Co PLC (PRGO) Q2 2022 Earnings Call Transcript first appeared on AlphaStreet .